GCP
MNPR icon

GSA Capital Partners’s Monopar Therapeutics MNPR Stock Holding History

GSA Capital Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$697K Buy
+7,532
New +$466K 0.04% 761

Other funds holding MNPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
GL
Gerber LLC Columbus, Ohio $213M AUM 25.63% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GSA Capital Partners's MNPR Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 7,532 shares worth $697K. The stake represents 0.04% of the portfolio and ranks #761 among its holdings.

19 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • GSA Capital Partners held 7,532 shares of Monopar Therapeutics worth $697K as of Q2 2026.
  • Monopar Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Monopar Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #761 holding.
  • 19 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.